GFAP and Alzheimer disease: Additionally, NfL is used to evaluate treatment effects in clinical trials, for example in AD, as a reduction in NfL levels indicates a slower neurodegeneration, although p-tau217 and glial fibrillary acidic protein (GFAP) are suited better for monitoring purposes [74].